-
Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes Semin. Hematol. (IF 5.0) Pub Date : 2024-08-03 Mary M. Czech, Eduard Schulz, Alain Mina, Juan Gea-Banacloche
Infectious complications are an important cause of morbidity and mortality in patients with myelodysplastic syndromes (MDS). Preventing infections could significantly improve both survival and quality of life. Unfortunately, both infections and antimicrobial prophylaxis in patients with MDS are incompletely assessed due to the heterogeneity of disorders included in each publication, changing definitions
-
License for a CAR T: Examining patient eligibility Semin. Hematol. (IF 5.0) Pub Date : 2024-07-06 Neha Akkad, Dai Chihara
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape of lymphoma and is now approved by the FDA for multiple indications. Given that the indications for CAR T-cell therapy are expanding, a larger patient population will be eligible to receive this treatment in the coming years. Pivotal clinical trials leading to FDA approval of CAR T-cell products required patients
-
Fast and furious: Changing gears on the road to cure with chimeric antigen receptor T cells in multiple myeloma Semin. Hematol. (IF 5.0) Pub Date : 2024-07-06 Nico Gagelmann, Maximilian Merz
Based on the pivotal KarMMa-1 and CARTITUDE-1 studies, Idecabtagene vicleucel (Ide-cel) and Ciltacabtagene autoleucel (Cilta-cel) have been approved to treat multiple myeloma patients, who have been exposed to at least 1 proteasome inhibitor, immunomodulatory drug and anti-CD38 antibody after 4 or 3 lines of therapy, respectively. The unprecedented rates of deep and long-lasting remissions have been
-
Tuning CAR T-cell therapies for efficacy and reduced toxicity Semin. Hematol. (IF 5.0) Pub Date : 2024-07-06 Danielle Blud, Patricia Rubio-Reyes, Rachel Perret, Robert Weinkove
Chimeric antigen receptor (CAR) T-cell therapies are a standard of care for certain relapsed or refractory B-cell cancers. However, many patients do not respond to CAR T-cell therapy or relapse later, short- and long-term toxicities are common, and current CAR T-cell therapies have limited efficacy for solid cancers. The gene engineering inherent in CAR T-cell manufacture offers an unprecedented opportunity
-
The role of response adapted therapy in the era of novel agents Semin. Hematol. (IF 5.0) Pub Date : 2024-06-14 Joseph G. Schroers-Martin, Ranjana H. Advani
The optimal treatment of classic Hodgkin Lymphoma (cHL) requires an individualized approach, with therapy guided by pretreatment clinical risk stratification and interim response assessment with positron emission tomography (PET). The overall goal is to achieve high cure rates while minimizing acute toxicity and late therapy-related effects. Interim PET-adapted strategies (iPET) were initially developed
-
The Management of older patients with Hodgkin lymphoma: implications of S1826 Semin. Hematol. (IF 5.0) Pub Date : 2024-06-04 Marshall McKenna, Yun Kyoung Ryu Tiger, Sarah C. Rutherford, Andrew M. Evens
Classical Hodgkin lymphoma (cHL) is diagnosed in patients ages 60 and older in approximately 20%–25% of cases in Western populations. Outcomes in this subset of patients have historically been poor, with 5-year progression free survival (PFS) and overall survival rates significantly lower than those seen in younger patients. Challenges to overcome include age-related co-morbidities, and prominent and
-
Molecular biomarkers in classic Hodgkin lymphoma Semin. Hematol. (IF 5.0) Pub Date : 2024-05-31 Makoto Kishida, Manabu Fujisawa, Christian Steidl
Classic Hodgkin lymphoma is a unique B-cell derived malignancy featuring rare malignant Hodgkin and Reed Sternberg (HRS) cells that are embedded in a quantitively dominant tumor microenvironment (TME). Treatment of classic Hodgkin lymphoma has significantly evolved in the past decade with improving treatment outcomes for newly diagnosed patients and the minority of patients suffering from disease progression
-
Contemporary radiation therapy use in Hodgkin lymphoma Semin. Hematol. (IF 5.0) Pub Date : 2024-05-31 Omran Saifi, Bradford S. Hoppe
Radiation therapy assumes a pivotal role in Hodgkin lymphoma management, especially within combined modality therapy. It serves as a cornerstone in early-stage disease and in mitigating high-risk instances of local relapse in advanced stages. Over recent decades, radiation therapy has undergone significant advancements, notably alongside diagnostic imaging improvements, facilitating the reduction of
-
The pediatric approach to Hodgkin lymphoma Semin. Hematol. (IF 5.0) Pub Date : 2024-05-15 Mallorie B. Heneghan, Jennifer A. Belsky, Sarah A. Milgrom, Christopher J. Forlenza
Hodgkin lymphoma (HL) occurs throughout the lifespan but is one of the most common cancers in adolescents and young adults (AYA; 15-39 years). HL has become a highly curable disease with survival rates surpassing 90%, including patients with high-risk and advanced stage disease. Unfortunately, intensive treatment carries a risk of short- and long-term toxicity. Given the decades pediatric HL survivors
-
Lessons learned from the Eµ-TCL1 mouse model of CLL Semin. Hematol. (IF 5.0) Pub Date : 2024-05-10 Alessia Floerchinger, Martina Seiffert
The Eµ-TCL1 mouse model has been used for over 20 years to study the pathobiology of chronic lymphocytic leukemia (CLL) and for preclinical testing of novel therapies. A CLL-like disease develops with increasing age in these mice due to a B cell specific overexpression of human . The reliability of this model to mirror human CLL is controversially discussed, as none of the known driver mutations identified
-
The biology of classical Hodgkin lymphoma Semin. Hematol. (IF 5.0) Pub Date : 2024-05-08 Samuel Kosydar, Stephen M. Ansell
Classical Hodgkin lymphoma (cHL) is distinguished by several important biological characteristics. The presence of Hodgkin Reed Sternberg (HRS) cells is a defining feature of this disease. The tumor microenvironment with relatively few HRS cells in an expansive infiltrate of immune cells is another key feature. Numerous cell-cell mediated interactions and a plethora of cytokines in the tumor microenvironment
-
The complexities of T-cell dysfunction in chronic lymphocytic leukemia Semin. Hematol. (IF 5.0) Pub Date : 2024-04-27 Elena Camerini, Derk Amsen, Arnon P. Kater, Fleur S. Peters
Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by profound alterations and defects in the T-cell compartment. This observation has gained renewed interest as T-cell treatment strategies, which are successfully applied in more aggressive B-cell malignancies, have yielded disappointing results in CLL. Despite ongoing efforts to understand and address the observed T-cell defects
-
Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia Semin. Hematol. (IF 5.0) Pub Date : 2024-04-17 John T. Patton, Jennifer A. Woyach
Aberrant signal transduction through the B cell receptor (BCR) plays a critical role in the pathogenesis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). BCR-dependent signaling is necessary for the growth and survival of neoplastic cells, making inhibition of down-stream pathways a logical therapeutic strategy. Indeed, selective inhibitors against Bruton's tyrosine kinase (BTK)
-
Mouse models of CLL: In vivo modeling of disease initiation, progression, and transformation Semin. Hematol. (IF 5.0) Pub Date : 2024-04-11 Shih-Shih Chen
Chronic lymphocytic leukemia (CLL) is a highly complex disease characterized by the proliferation of CD5 B cells in lymphoid tissues. Current modern treatments have brought significant clinical benefits to CLL patients. However, there are still unmet needs. Patients relapse on Bruton's tyrosine kinase inhibitors and BCL2 inhibitors and often develop more aggressive diseases including Richter transformation
-
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial Semin. Hematol. (IF 5.0) Pub Date : 2024-03-26 Barbara Eichhorst, Elisa ten Hacken
-
miRNA Biology in Chronic Lymphocytic Leukemia Semin. Hematol. (IF 5.0) Pub Date : 2024-03-19 Recep Bayraktar, Beatrice Fontana, George A. Calin, Kinga Nemeth
microRNAs (miRNAs) are a class of small non-coding RNAs that play a crucial regulatory role in fundamental biological processes and have been implicated in various diseases, including cancer. The first evidence of the cancer-related function of miRNAs was discovered in chronic lymphocytic leukemia (CLL) in the early 2000s. Alterations in miRNA expression have since been shown to strongly influence
-
Prognostication in chronic lymphocytic leukemia Semin. Hematol. (IF 5.0) Pub Date : 2024-03-01 Riccardo Moia, Gianluca Gaidano
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Western countries. CLL is a highly heterogeneous disease: some patients may never require therapy and others relapse several times after different therapeutic strategies. Therefore, in CLL, prognostic markers are essential to capture high-risk patients for different clinical endpoints including early treatment requirement, early
-
Metabolic reprogramming in the CLL TME; potential for new therapeutic targets Semin. Hematol. (IF 5.0) Pub Date : 2024-02-15 Helga Simon-Molas, Chiara Montironi, Anna Kabanova, Eric Eldering
Chronic lymphocytic leukemia (CLL) cells circulate between peripheral (PB) blood and lymph node (LN) compartments, and strictly depend on microenvironmental factors for proliferation, survival and drug resistance. All cancer cells display metabolic reprogramming and CLL is no exception – though the inert status of the PB CLL cells has hampered detailed insight into these processes. We summarize previous
-
Therapeutic targeting of apoptosis in chronic lymphocytic leukemia Semin. Hematol. (IF 5.0) Pub Date : 2024-02-07 Inhye E. Ahn, Matthew S. Davids
Therapeutic targeting of apoptosis with small molecule B-cell lymphoma 2 (BCL-2) inhibition with venetoclax is highly efficacious in CLL, leading to sustained deep responses, particularly among patients with treatment-naïve disease with favorable prognostic markers. Patients with unfavorable genetic characteristics such as aberration and unmutated IGHV may also derive durable benefits, but their remission
-
Clonal hematopoiesis Semin. Hematol. (IF 5.0) Pub Date : 2024-02-02 Jaroslaw P. Maciejewski
Abstract not available
-
Clonal hematopoiesis and autoimmunity Semin. Hematol. (IF 5.0) Pub Date : 2024-02-02 Ashwin Kishtagari, Robert W. Corty, Valeria Visconte
Clonal hematopoiesis (CH) has been associated with aging, occurring in about 10% of individuals aged >70 years, and immune dysfunction. Aged hematopoietic stem and progenitor cells exhibit pathological changes in immune function and activation of inflammatory pathways. CH clones commonly harbor a loss of function mutation in or , which causes increased expression of inflammatory signaling genes, a
-
TET2 mutation as prototypic clonal hematopoiesis lesion Semin. Hematol. (IF 5.0) Pub Date : 2024-02-02 Luca Guarnera, Babal K. Jha
Loss of function mutation () is one of the most frequently observed lesions in clonal hematopoiesis (CH). TET2 a member TET-dioxygenase family of enzymes that along with TET1 and TET3, progressively oxidize 5-methyl cytosine (mC) resulting in regulated demethylation of promoter, enhancer and silencer elements of the genome. This process is critical for efficient transcription that determine cell lineage
-
Clonal hematopoiesis in the setting of hematopoietic cell transplantation Semin. Hematol. (IF 5.0) Pub Date : 2024-02-01 Christopher J. Gibson, R. Coleman Lindsley, Lukasz P. Gondek
-
Introduction to series: Diffuse large B-cell lymphoma Semin. Hematol. (IF 5.0) Pub Date : 2024-01-26 Sonali M. Smith, Laura Pasqualucci
Abstract not available
-
The molecular map of CLL and Richter's syndrome Semin. Hematol. (IF 5.0) Pub Date : 2024-01-23 Amit Sud, Erin M. Parry, Catherine J. Wu
Clonal expansion of B-cells, from the early stages of monoclonal B-cell lymphocytosis through to chronic lymphocytic leukemia (CLL), and then in some cases to Richter's syndrome (RS) provides a comprehensive model of cancer evolution, notable for the marked morphological transformation and distinct clinical phenotypes. High-throughput sequencing of large cohorts of patients and single-cell studies
-
Looking to achieve cure the first time around for DLBCL patients who are older and/or with co-morbidities Semin. Hematol. (IF 5.0) Pub Date : 2024-01-22 Elizabeth A. Brem, Laurie H. Sehn
Diffuse large B-cell lymphoma (DLBCL) is an aggressive but often curable malignancy. Older patients, especially those 80 years and older, have poor outcomes compared to those < 60, likely due to a number of reasons including disease biology, comorbidities, and treatment intolerance. Prospective data informing the treatment of older patients and those with multiple co-morbidities is limited. Here, we
-
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS Semin. Hematol. (IF 5.0) Pub Date : 2024-01-19 Carlos Bravo-Perez, Carmelo Gurnari
With the advent of outperforming and massive laboratory tools, such as multiparameter flow cytometry and next-generation sequencing, hematopoietic cell clones with putative abnormalities for a variety of blood malignancies have been appreciated in otherwise healthy individuals. These conditions do not fulfill the criteria of their presumed cancer counterparts, and thus have been recognized as their
-
The crossroads of cancer therapies and clonal hematopoiesis Semin. Hematol. (IF 5.0) Pub Date : 2024-01-18 Abhay Singh, Suresh Balasubramanian
The intricate interplay between Clonal Hematopoiesis (CH) and the repercussions of cancer therapies has garnered significant research focus in recent years. Previously perceived as an age-related phenomenon, CH is now closely linked to inflammation (“Inflammaging”) and cancer, impacting leukemogenesis, cancer progression, and treatment responses. This review explores the complex interplay between CH
-
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence Semin. Hematol. (IF 5.0) Pub Date : 2024-01-17 Simona Pagliuca, Francesca Ferraro
Immune surveillance mechanisms play a crucial role in maintaining lifelong immune homeostasis in response to pathologic stimuli and aberrant cell states. However, their persistence, especially in the context of chronic antigenic exposure, can create a fertile ground for immune evasion. These escaping cell phenotypes, harboring a variety of genomic and transcriptomic aberrances, chiefly in human leukocyte
-
Germline predisposition for clonal hematopoiesis Semin. Hematol. (IF 5.0) Pub Date : 2024-01-14 Yasuo Kubota, Aaron D. Viny
Clonal hematopoiesis (CH) is an entity hallmarked by skewed hematopoiesis with persistent overrepresentation of cells from a common stem/progenitor lineage harboring single-nucleotide variants and/or insertions/deletions. CH is a common and age-related phenomenon that is associated with an increased risk of hematological malignancies, cardiovascular disease, and all-cause mortality. While CH is a term
-
Clonal hematopoiesis in children with predisposing conditions Semin. Hematol. (IF 5.0) Pub Date : 2024-01-14 Enrico Attardi, Seth J. Corey, Marcin W. Wlodarski
Clonal hematopoiesis in children and young adults differs from that occuring in the older adult population. A variety of stressors drive this phenomenon, sometimes independent of age-related processes. For the purposes of this review, we adopt the term clonal hematopoiesis in predisposed individuals (CHIPI) to differentiate it from classical, age-related clonal hematopoiesis of indeterminate potential
-
Vaccinations in patients with chronic lymphocytic leukemia Semin. Hematol. (IF 5.0) Pub Date : 2024-01-06 Elizabeth R. Francis, Jennifer Vu, Catherine Ostos Perez, Clare Sun
Chronic lymphocytic leukemia (CLL) is characterized by immune dysfunction resulting in heightened susceptibility to infections and elevated rates of morbidity and mortality. A key strategy to mitigate infection-related complications has been immunization against common pathogens. However, the immunocompromised status of CLL patients poses challenges in eliciting an adequate humoral and cellular immune
-
Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies Semin. Hematol. (IF 5.0) Pub Date : 2024-01-05 Azra Borogovac, Tanya Siddiqi
Immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies or T-cell engagers, have revolutionized the treatment landscape for various B-cell malignancies, including B-acute lymphoblastic leukemia and many non-Hodgkin lymphomas. Despite their significant impact on these malignancies, their application in chronic lymphocytic leukemia (CLL) management is still largely
-
Role of the tumor microenvironment in CLL pathogenesis Semin. Hematol. (IF 5.0) Pub Date : 2023-12-26 Alexander F. vom Stein, Michael Hallek, Phuong-Hien Nguyen
Chronic lymphocytic leukemia (CLL) cells extensively interact with and depend on their surrounding tumor microenvironment (TME). The TME encompasses a heterogeneous array of cell types, soluble signals, and extracellular vesicles, which contribute significantly to CLL pathogenesis. CLL cells and the TME cooperatively generate a chronic inflammatory milieu, which reciprocally reprograms the TME and
-
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients Semin. Hematol. (IF 5.0) Pub Date : 2023-12-26 Andreas Agathangelidis, Thomas Chatzikonstantinou, Kostas Stamatopoulos
Sequence convergence, otherwise stereotypy, of B-cell receptor immunoglobulin (BcR IG) from unrelated patients is a distinctive feature of the IG gene repertoire in chronic lymphocytic leukemia (CLL) whereby patients expressing a particular BcR IG archetype are classified into groups termed stereotyped subsets. From a biological perspective, the fact that a considerable fraction (∼41%) of patients
-
Integration of PET in DLBCL Semin. Hematol. (IF 5.0) Pub Date : 2023-12-24 Katharine L Lewis, Judith Trotman
F-fluorodeoxyglucose positron emission tomography-computerized tomography (FDG-PET/CT) is the gold-standard imaging modality for staging and response assessment for most lymphomas. This review focuses on the utility of FDG-PET/CT, and its role in staging, prognostication and response assessment in diffuse large B-cell lymphoma (DLBCL), including emerging possibilities for future use.
-
Second-line treatment of diffuse large B‐cell lymphoma: Evolution of options Semin. Hematol. (IF 5.0) Pub Date : 2023-12-14 N. Fabbri, A. Mussetti, A. Sureda
In the era of immunochemotherapy, approximately 60%-70% of diffuse large B-cell lymphoma (DLBCL) patients achieve remission with first-line rituximab-based chemoimmunotherapy. However, 30%-40% relapse after initial response to first-line therapy and, out of them, 20%-50% are refractory or experience early relapse. The second-line therapy algorithm for DLBCL has recently evolved, thanks to the recent
-
Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023 Semin. Hematol. (IF 5.0) Pub Date : 2023-12-12 Christine E. Ryan, Caron A. Jacobson
Over the last decade, CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has profoundly changed the management of relapsed/refractory large-B-cell lymphoma (LBCL). At present, there are three FDA-approved anti-CD19 CAR T-cell products for LBCL: axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel). Two of these (axi-cel & liso-cel) are approved
-
CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail? Semin. Hematol. (IF 5.0) Pub Date : 2023-12-05 Hannah Kinoshita, Catherine M. Bollard, Keri Toner
Chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed or refractory diffuse large B cell lymphoma (DLBCL) with 3 CD19 targeting products now FDA-approved for this indication. However, up to 60% of patients ultimately progress or relapse following CAR-T cell therapy. Mechanisms of resistance to CAR-T cell therapy in patients with DLBCL are likely multifactorial and
-
Biological heterogeneity in diffuse large B-cell lymphoma Semin. Hematol. (IF 5.0) Pub Date : 2023-12-01 Laura K. Hilton, David W. Scott, Ryan D. Morin
Diffuse large B-cell lymphoma (DLBCL) is heterogeneous both in clinical outcomes and the underlying disease biology. Over the last 2 decades, several different approaches for dissecting biological heterogeneity have emerged. Gene expression profiling (GEP) stratifies DLBCL into 3 broad groups (ABC, GCB, and DZsig/MHG), each with parallels to different normal mature B cell developmental states and prognostic
-
Biological, prognostic, and therapeutic impact of the epigenome in CLL Semin. Hematol. (IF 5.0) Pub Date : 2023-12-01 Alba Maiques-Diaz, Jose Ignacio Martin-Subero
Chronic lymphocytic leukemia (CLL) is characterized by widespread alterations in the genetic and epigenetic landscapes which seem to underlie the variable clinical manifestations observed in patients. Over the last decade, epigenomic studies have described the whole-genome maps of DNA methylation and chromatin features of CLL and normal B cells, identifying distinct epigenetic mechanisms operating
-
Evidence-based management of primary and secondary CNS lymphoma Semin. Hematol. (IF 5.0) Pub Date : 2023-12-01 Jahanzaib Khwaja, Lakshmi Nayak, Kate Cwynarski
Central nervous system (CNS) lymphoma has traditionally had very poor outcomes however advances in management have resulted in dramatic improvements and long-term survival of patients. We describe the evidence for treatment strategies for these aggressive disorders. In primary CNS lymphoma there are randomized trial data to inform treatment decisions but these are lacking to guide management in secondary
-
Epidemiology and etiology of diffuse large B-cell lymphoma Semin. Hematol. (IF 5.0) Pub Date : 2023-11-27 Sophia S. Wang
As the most common non-Hodgkin lymphoma subtype, diffuse large B-cell lymphoma (DLBCL) incidence patterns generally parallel that for NHL overall. Globally, DLBCL accounts for a third of all NHLs, ranging between 20% and 50% by country. Based on United States (U.S.) cancer registry data, age-standardized incidence rate for DLBCL was 7.2 per 100,000. DLBCL incidence rises with age and is generally higher
-
Antibody and immunotherapy in diffuse large B-cell lymphoma Semin. Hematol. (IF 5.0) Pub Date : 2023-11-23 Allison Barraclough, Eliza A. Hawkes
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma and a heterogeneous B-cell disease. The majority of patients with newly diagnosed disease are cured with first-line combination immunochemotherapy treatment however, those who experience treatment failure have dismal outcomes. Antibody therapies and immunotherapy have provided the single most major advance in the treatment of DLBCL in
-
DLBCL arising from indolent lymphomas: How are they different? Semin. Hematol. (IF 5.0) Pub Date : 2023-11-23 Erin M. Parry, Sandrine Roulland, Jessica Okosun
Transformation to diffuse large B-cell lymphoma (DLBCL) is a recognized, but unpredictable, clinical inflection point in the natural history of indolent lymphomas. Large retrospective studies highlight a wide variability in the incidence of transformation across the indolent lymphomas and the adverse outcomes associated with transformed lymphomas. Opportunities to dissect the biology of transformed
-
outside front cover, PMS 8883 metallic AND 4/C Semin. Hematol. (IF 5.0) Pub Date : 2023-11-14
Abstract not available
-
-
Debate: Should the loss of disability adjusted life years (DALY) define the focus of Global Hematology?: The case for prioritizing capacity building in anemia management and blood transfusion Semin. Hematol. (IF 5.0) Pub Date : 2023-09-30 David J. Roberts, Aggrey Dhabangi
Setting priorities in healthcare is always contentious given the array of possible services at primary, secondary, and tertiary levels of care, not to mention potential public health interventions. The central goals in global policy have been reducing inequity within and between countries, protecting vulnerable groups (particularly women and children) and reducing the major communicable diseases which
-
Special edition of the Seminars in Hematology series on Global Hematology Care Semin. Hematol. (IF 5.0) Pub Date : 2023-09-27 Anna Schuh
Abstract not available
-
The future of aplastic anemia treatment in Brazil: Lessons learned for global hematology Semin. Hematol. (IF 5.0) Pub Date : 2023-09-24 Rodrigo T. Calado
Aplastic anemia (AA) is a rare serious hematologic disorder caused by hematopoietic stem cell failure in maintaining hematopoiesis. AA is virtually fatal if not treated, and diagnosis and therapy require extensive hematologic infrastructure. Academic medical centers in Brazil have continuously and significantly contributed to diagnostic tools and therapy development, from novel transplant strategies
-
outside front cover, PMS 8883 metallic AND 4/C Semin. Hematol. (IF 5.0) Pub Date : 2023-09-13
Abstract not available
-
How to set up a clinical research center in Brazil, as an example of a middle-income country Semin. Hematol. (IF 5.0) Pub Date : 2023-09-04 Eduardo Flávio Oliveira Ribeiro, Ana Amélia Morais de Lacerda Mangueira Belmiro, Lenisa Cezar Vilas Boas, Carsten Utoft Niemann
In health care, innovation is a core part of the process that pushes advances forward. Drug and device development follow a step-by-step process from the discovery of a molecule to the final product. While patent filing and preclinical studies are usually performed by academic centers or start-ups, the clinical development is usually performed by pharmaceutical companies. To assess safety, efficacy
-
The case for prioritizing malignant hematology services in low- and middle-income countries Semin. Hematol. (IF 5.0) Pub Date : 2023-09-02 Satish Gopal
A clear case for can be made for prioritizing malignant hematology services in low- and middle-income countries based on large public health burden, convincing demonstrations of cure and control, innovation opportunities with likely worldwide implications, and sizable returns on investment for health systems and societies. We must now ensure that need and opportunity are matched by commensurate levels
-
Forging international collaboration and alliances to establish the largest transplant center in the north of Vietnam Semin. Hematol. (IF 5.0) Pub Date : 2023-09-01 Bach Quoc Khanh, Vo Thi Thanh Binh, Nguyen Ha Thanh, Dao Phan Thu Huong, Do Thi Thuy, Nguyen Khanh Ha, Richard W. Childs
Through collaboration with international experts, our institution established a highly active and successful hematopoietic stem cell transplant program, providing access to this potentially curative treatment modality for patients with a variety of benign and malignant hematological diseases. The initial development of an autologous stem cell transplant program provided our institution with the infrastructure
-
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa Semin. Hematol. (IF 5.0) Pub Date : 2023-08-24 Mwashungi Ally, Emmanuel Balandya
Sickle cell disease (SCD) is the most common life-threatening monogenic disorder in the world. The disease is highly prevalent in malaria endemic areas with over 75% of patients residing in Sub-Saharan Africa (SSA). It is estimated that, without proper care, up to 90% of children with SCD will not celebrate their fifth birthday. Early identification and enrolment into comprehensive care has been shown
-
Special issue on circulating tumor DNA: Introductory editorial Semin. Hematol. (IF 5.0) Pub Date : 2023-08-19 Adalgisa Condoluci, Davide Rossi
Abstract not available
-
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services Semin. Hematol. (IF 5.0) Pub Date : 2023-08-01 Clara Chamba, William Mawalla
The world is moving towards precision medicine for cancer. This movement goes hand in hand with the development of newer advanced technologies for early, precise diagnosis of cancer and personalized treatment plans with fewer adverse effects for the patient. Liquid biopsy is one such advancement. At the same time, it has the advantage of minimal invasion and avoids serial invasive biopsies. In countries
-
Circulating tumor DNA in NK/T and peripheral T cell lymphoma Semin. Hematol. (IF 5.0) Pub Date : 2023-07-26 Yu-Jia Huo, Wei-Li Zhao
Natural killer (NK)/T-cell lymphomas (NK/TCL) and peripheral T-cell lymphomas (PTCL) are aggressive hematological malignancies. With the development of next-generation sequencing, circulating tumor DNA (ctDNA) can be detected by several techniques with clinical implications. So far, the effect of ctDNA in pretreatment prognosis prediction, longitudinal monitoring of treatment response and surveillance
-
Palliative care needs of patients with hematologic malignancies and family caregivers and challenges of palliative care provision in Asia: A review of evidence Semin. Hematol. (IF 5.0) Pub Date : 2023-07-22 Yupawadee Kantabanlang, Cheng-Pei Lin, Kittikorn Nilmanat, Ping Guo
Patients with hematologic malignancies often experience fatigue, lack of vitality, and energy, and high psychological distress. High levels of unmet care needs of patients with hematologic malignancies in Asia were identified. This review provides an overview of current evidence on the experiences and palliative care needs of patients with hematologic malignancies and their families and the barriers
-
Inequalities in access to treatment in Argentina: Differences in management of CLL and multiple myeloma? Semin. Hematol. (IF 5.0) Pub Date : 2023-07-15 María José Mela Osorio, Carolina Pavlovsky, Miguel Arturo Pavlovsky
Health equity is today an important objective to evenly reach the population among different health care systems. This article will focus on diagnosis and treatment access inequalities in Argentina. Although different aspects must be optimized to overcome access barriers worldwide, access inequalities in some regions of Argentina may depend basically on the type of health coverage or insurance. Health